Physician profile
Payal Kohli
NPI 1447459771
$1,718,232.18
in general payments reported to CMS, 2019-2025
28 companies · $523K in 2025
The $523K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $41K · 2021: $171K · 2022: $289K · 2023: $330K · 2024: $343K · 2025: $523K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $782K · Consulting Fee: $241K · Travel and Lodging: $141K · Food and Beverage: $21K · Education: $5,111 · Honoraria: $5,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $782,345.12 |
| Consulting Fee | $240,581.68 |
| Travel and Lodging | $141,210.05 |
| Food and Beverage | $21,387.55 |
| Education | $5,110.89 |
| Honoraria | $5,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $332,550.18 | 2020-2025 | Repatha, Repatha, Prolia |
| Esperion Therapeutics, INC. | $295,971.16 | 2020-2024 | Nexletol, Nexlizet |
| Merck Sharp & Dohme LLC | $217,602.60 | 2021-2025 | Verquvo |
| Amarin Pharma, INC. | $160,572.72 | 2020-2025 | Vascepa |
| Bayer Healthcare Pharmaceuticals INC. | $152,998.78 | 2023-2025 | |
| Lilly USA, LLC | $101,291.57 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $93,622.51 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Boston Scientific Corporation | $87,401.10 | 2019-2023 | Watchman Access System, Watchman |
| E.R. Squibb & Sons, L.L.C. | $63,380.03 | 2023-2025 | Camzyos |
| Heartflow, INC. | $47,539.41 | 2022-2025 | Ffrct |
| Astrazeneca Pharmaceuticals Lp | $46,304.22 | 2021-2024 | Farxiga, Lokelma |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $44,515.68 | 2022-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25,905.42 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $25,881.51 | 2021-2025 | Leqvio |
| Agepha Pharma Fz LLC | $15,021.66 | 2024-2025 | Lodoco |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $3,179.00 | 2024 | Tryvio |
| Abbott Laboratories | $1,670.30 | 2019-2024 | Confirm Rx, Aveir, Assurity |
| Medtronic Vascular, INC. | $1,122.20 | 2019 | |
| Biotronik INC. | $753.49 | 2021-2023 | Biomonitor |
| Artivion, INC. | $525.73 | 2019-2020 | |
| Philips North America LLC | $124.37 | 2020-2025 | (Ck4) Mcot, Extended Holter, Ambulatory Monitoring & Diagnostics Undivided |
| Lexicon Pharmaceuticals, INC. | $68.86 | 2023-2025 | Inpefa |
| Medtronic, INC. | $64.82 | 2021-2022 | |
| Pfizer INC. | $57.42 | 2023-2024 | |
| Scpharmaceuticals INC. | $44.57 | 2024-2025 | |
| Sanofi Pasteur INC. | $24.63 | 2020 | |
| Kiniksa Pharmaceuticals, Ltd. | $21.60 | 2022 | |
| Medicure Pharma INC. | $16.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Payal Kohli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.